Mateon Therapeutics Provides Business Update and Reports 2017 Financial Results

14-day Study of PTI-801, Company's Third Generation Corrector, in CF Patients on Background Orkambi® Enrolling Ahead of Schedule; Results from All Three Cohorts Expected Q2'18 Company Announces Additional Study of PTI-428 in CF.....»»

Completes Sale of Hyperimmune Commercial Business for up to $74.5 Million Forms Strategic Bispecific Antibody Partnership with Alligator Bioscience Demonstrating Versatility of the ADAPTIR™ Technology Platform Advances Multiple AD.....»»

- On track to begin first company-sponsored clinical trials of a CRISPR-based therapy -- Wholly-owned CRISPR-based allogeneic CAR-T programs advancing rapidly - ZUG, Switzerland and CAMBRIDGE, Mass., March .....»»

Interim analyses of STRIDE-1 and ADVANCE-1 trials of AXS-05 anticipated in 2018 Company to host conference call today at 8:00 AM Eastern NEW YORK, March 07, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a .....»»

All 52 weeks of infusions and 100% of the doses have been administered in the NASH Cirrhosis, NASH-CX Phase 2b Clinical Trial Top Line Results of NASH-CX Phase 2b Clinical Trial Expe.....»»

WARREN, N.J., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (NASDAQ:BLPH), a clinical-stage biotherapeutics company, today provided a business update and reported financial results for the third quarter .....»»

NORCROSS, Ga., Aug. 18, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:G.....»»

NORCROSS, Ga., Aug. 14, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today repor.....»»

NEW YORK, Aug. 09, 2017 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX) today announced its financial results for the second quarter ended June 30, 201.....»»

WARREN, N.J., Aug. 07, 2017 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (NASDAQ:BLPH), a clinical-stage biotherapeutics company, today provided a business updat.....»»

- Recent initiation of STAR phase 3 trial in Choroideremia - - Begins 2018 with a cash position over $129 million - LEXINGTON, Mass. and LONDON, April 03, 2018 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc (NASDAQ:NITE), .....»»

Patient Enrollment in Phase 3 Inoperable GBM Brain Cancer Trial Underway Raised $12 Million in Underwritten Public Offering Preparing to Commence Clinical Trial with TSC in Stroke Expanded Intellectual Property Portfol.....»»

Net Element Reports Full-Year 2017 Financial Results and Provides Business Update.....»»

SANUWAVE Health Reports 2017 Financial Results and Provides a Business Update.....»»

 -- Initiated URIROX-1™, First Phase.....»»

SOUTH SAN FRANCISCO, Calif., March 19, 2018 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ:DNLI), a biopharmaceutical company developing a broad portfolio of therapeutic candidates for neurodegenerative diseases, today announced that it.....»»

Company to host webcast and conference call on Tuesday, March 20, 2018 at 8 am ET Management to discuss recent data and progress on development plans WALTHAM, Mass., March 19, 2018 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. ("Eloxx") .....»»

NEW YORK and CLEVELAND, March 16, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene th.....»»

OpGen Reports Fourth Quarter and Full Year 2017 Financial Results and Provides a Business Update.....»»

Adaptimmune Reports Fourth Quarter / Full Year 2017 Financial Results and Business Update.....»»